Healthcare Private Placement and M&A Transactions Review Week Ending October 29, 2023

Aiolos Bio: The company raised $245 million of Series A venture funding in a deal led by Atlas Venture, Bain Capital Life Sciences, Forbion and Sofinnova Investments on October 24, 2023. RA Capital Management also participated in the round. The company is an operator of a clinical-stage biopharmaceutical company intended to focus on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions.

Triveni Bio: The company raised $92 million of Series A venture funding in a deal led by Atlas Venture and Cormorant Asset Management on October 26, 2023. Alexandria Venture Investments, OrbiMed, The Invus Group, Polaris Partners, Viking Global Investors, and other undisclosed investors also participated in the round. The company is a developer of a drug discovery platform intended to target therapies for inflammation and immunology disorders.

Rampart Bioscience: The company received $85 million of development capital led by Forbion. OrbiMed, HealthCap and RA Capital Management also participated in the round on October 24, 2023. The company is a developer of gene medicines intended to provide long-lasting treatments for a wide range of genetic diseases.

DermBiont: The company raised $35.2 million of Series B venture funding in a deal led by Double Point Ventures on October 24, 2023. Civilization Ventures, Viking Global Investors, Olive Tree Capital and others also participated in the round. The company is a developer of microbial and targeted topical therapeutics designed to treat, cure and prevent skin diseases.

LyGenesis: The company raised $19 million of Series A2 venture funding in a deal led by Prime Movers Lab on October 24, 2023. Juvenescence also participated in the round. The company is a developer of a cell therapy technology designed to facilitate organ regeneration and transplant.

ENSEM Therapeutics: The company raised $10 million of Series A+ venture funding from undisclosed investors on October 23, 2023. The company is a developer of molecule precision medicines for oncology.

Switchback Systems: The company raised $6.7 million of venture funding from OMX Ventures, Vertical Venture Partners and Ahren Innovation Capital on October 24, 2023. The company is an operator of a DNA synthesis platform intended to develop technologies that use cell structure as a data storage medium.

Planatome: The company raised $6 million in a combination of convertible debt and Series A venture funding from undisclosed investors on October 25, 2023. The company is a developer of a medical technology focused on applying nano-polishing technology used in microchip manufacturing to surgical devices.

Samay: The company announced it will raise $4M of venture funding by 2024 on October 26, 2023. The company is a developer of an AI-enabled wearable device and platform designed for respiratory health management.

Owl Peak Technologies: The company raised an undisclosed amount of venture funding from Virginia Venture Partners on October 27, 2023. The company is a developer of a diagnostic imaging technology designed to detect early-stage colorectal cancer.

Telavant / Roche: The company reached a definitive agreement to be acquired by Roche for an $ 7.2 billion on October 23, 2023. The company is a developer of innovative drugs and therapies intended to serve patients living with inflammatory and fibrotic diseases.

Xoft / Elekta: The company, a subsidiary of iCAD was acquired by Elekta for $5.5 million on October 23, 2023. The company is a developer of electronic brachytherapy (eBx) systems intended for radiation and oncology applications.

AllStripes / PicnicHealth: The company was acquired by PicnicHealth for an undisclosed amount on October 23, 2023. The company is a developer of a drug research and tracking platform designed to accelerate drug development for rare diseases.

Citius Oncology / TenX Keane Acquisition: The company reached a definitive agreement to acquire TenX Keane Acquisition through a reverse merger, resulting in the combined entity trading on the Nasdaq Stock Exchange on October 23, 2023. The company is a developer of anti-infectives in adjunct cancer care, oncology, stem cell therapy and unique prescription products, and is based in Cranford, New Jersey.

Infirst Healthcare / Carlin Consumer Health: The company was acquired by Carlin Consumer Health through an LBO on October 24, 2023 for an undisclosed amount. The company is a producer of medicines intended to enhance the treatment of the common cold, inflammatory pain and chronic wounds.

NAYA Biosciences / Invo Bioscience: The company reached a definitive agreement to acquire Invo Bioscience through a reverse merger on October 23, 2023. The merger reportedly values the combined entity at close to $103 million. The biotechnology company focuses on increasing patient access to treatments in oncology, fertility, and regenerative medicine.

Securedose Synthetics / Pharmadrug: The company reached a definitive agreement to be acquired by Pharmadrug for an undisclosed amount on October 27, 2023. The company is an operator of a pharmaceutical research and development company focused on the development of synthetic formulations of currently existing drugs for commercialization and distribution.

XingImaging / Mitro Biotech: The company was acquired by Mitro Biotech, a subsidiary of Yantai Dongcheng Pharmaceutical Group, for an undisclosed amount on October 23, 2023. The company is an operator of a clinical PET imaging service business based in Madison, Connecticut.